Trial Profile
An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Filgrastim; Plerixafor
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 May 2021 Status changed from active, no longer recruiting to completed.
- 10 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Oct 2020.
- 10 Feb 2020 Status changed from recruiting to active, no longer recruiting.